PR PolyResearch

Join Free

NASDAQ

DexCom, Inc. (DXCM)

♥ 547 Thanks from members

DexCom, Inc. (DXCM) displays a cautiously bullish net sentiment driven by strong Q2 earnings, raised FY2026 guidance, and expanding type 2 diabetes coverage, tempered by valuation concerns, intense competition, and upcoming Medicare reimbursement headwind risks starting in 2028.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)